Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron to Present at the Needham & Company 7th Annual Biotechnology and Medical Technology Conference
Acceleron to Present at the Needham & Company 7th Annual Biotechnology and Medical Technology Conference CAMBRIDGE, Mass. – June 4, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced
View HTML
Toggle Summary A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. PNAS 2008; 105(19): 7082-7087
A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. PNAS 2008; 105(19): 7082-7087 A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. PNAS 2008; 105(19): 7082-7087
View HTML
Toggle Summary Acceleron to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Acceleron to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference CAMBRIDGE, Mass. – May 13, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that Steven Ertel,
View HTML
Toggle Summary ACE-011 Preclinical Data Published in the Proceedings of the National Academy of Sciences
Results demonstrate ACE-011 increases bone formation, bone mass and bone strength
View HTML
Toggle Summary Acceleron Pharma and Celgene Corporation Receive Hart-Scott-Rodino Clearance for ACE-011 Collaboration
Acceleron Pharma and Celgene Corporation Receive Hart-Scott-Rodino Clearance for ACE-011 Collaboration CAMBRIDGE, Mass. – March 24, 2008 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced
View HTML
Toggle Summary Acceleron to Present at the Cowen and Company 28th Annual Health Care Conference
Acceleron to Present at the Cowen and Company 28th Annual Health Care Conference CAMBRIDGE, Mass. – March 11, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf,
View HTML
Toggle Summary BioCentury: Bone Loss is Acceleron’s Gain
BioCentury: Bone Loss is Acceleron’s Gain BioCentury Feb 25, 2008
View HTML
Toggle Summary BioWorld Today: Acceleron, Celgene in Potential $1.8B Bone Loss Collaboration
BioWorld Today: Acceleron, Celgene in Potential $1.8B Bone Loss Collaboration BioWorld Today, Feb 21, 2008
View HTML
Toggle Summary Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss
Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss CAMBRIDGE, Mass. & SUMMIT, N.J.– Feb. 20, 2008 – Acceleron Pharma, Inc. and Celgene Corporation today announced a worldwide strategic collaboration for the joint development and
View HTML
Toggle Summary Acceleron Pharma Receives Grant for ACE-011 from the Multiple Myeloma Research Foundation
Acceleron Pharma Receives Grant for ACE-011 from the Multiple Myeloma Research Foundation Cambridge, Mass. – January 23, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that it
View HTML